Is AstraZeneca (AZN) a Good Investment in 2026?

AstraZeneca is a global biopharma company with meaningful scale across oncology, cardiovascular, renal and metabolism, respiratory and immunology, vaccines and immune therapies, and rare disease. In FY 2025, oncology accounted for 44% of total revenue, CVRM 22%, R&I 15%, and rare disease 16%, which matters because it reduces reliance on any single medicine.

• FY 2025 total revenue rose 8% at constant exchange rates to $58.7bn, while core EPS increased 11% to $9.16.
• Management guided FY 2026 revenue to grow by a mid-to-high single-digit percentage and core EPS by a low double-digit percentage.
• The company reported 16 positive Phase 3 readouts and 43 approvals in major regions over the last twelve months.
• AstraZeneca ordinary shares began trading on the NYSE on 2 February 2026, widening access for US investors.

Long-term view: AstraZeneca looks like a good long-term investment if you want quality growth and can accept paying more than a market-average multiple for it.

AstraZeneca does not need to be cheap to work, but it probably does need to keep executing. That is the main valuation lens to use here.

Assessment: The shares look closer to fairly valued or slightly expensive than obviously undervalued.

• A premium multiple is easier to justify here than for slower-growing pharma peers because AstraZeneca still has visible growth engines.
• The stock is not priced for distress, so returns depend more on sustained execution than on multiple expansion.
• Net debt fell to $23.4bn by the end of FY 2025, which supports the quality case but does not turn the shares into a bargain.

Most important right now: paying a quality multiple just before growth slows — the current share price already assumes AstraZeneca can keep delivering strong launches, healthy margins and new pipeline wins

Takeaway: If you want the cleaner growth story, AstraZeneca is compelling. If you want a cheaper or more income-led setup, some peers may look more comfortable.

Treating AstraZeneca like a simple defensive dividend stock.

• The company is defensive compared with cyclical sectors, but stock returns still depend heavily on pipeline execution and launch traction.
• At today's valuation, you are buying continued growth and quality, not just a safe dividend stream.

AstraZeneca looks like a good investment for long-term investors, but the thesis is quality compounding rather than obvious undervaluation. If you are comfortable paying up for execution, pipeline depth and relatively low stock risk, AZN makes sense. If you need a margin-of-safety valuation, it is harder to call it cheap.

Is AstraZeneca a good long-term investment?

For many long-term investors, yes. AstraZeneca combines scale, diversified drug revenue, a live late-stage pipeline and relatively low stock-level risk, although the shares are not obviously cheap.

Is AstraZeneca stock undervalued right now?

Probably not in an obvious way. AstraZeneca looks more fairly valued to slightly expensive than deeply undervalued, especially on trailing earnings multiples.

Does AstraZeneca pay a dividend?

Yes. AstraZeneca declared a total FY 2025 dividend of $3.20 per share and has indicated an intention to raise the annual dividend to $3.30 for FY 2026.

What is the biggest risk with AstraZeneca stock?

The biggest risk is that investors are paying for continued strong execution. If growth slows because of weaker trial readouts, pricing pressure or competition, the multiple can fall.

Is AstraZeneca more of a growth stock or a defensive stock?

It is a mix of both. AstraZeneca is more defensive than cyclical sectors, but the return case still depends on growth from oncology, CVRM, rare disease and new launches.